<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040686</url>
  </required_header>
  <id_info>
    <org_study_id>2019/52</org_study_id>
    <nct_id>NCT04040686</nct_id>
  </id_info>
  <brief_title>HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT</brief_title>
  <official_title>Technetium-99m Labeled Anti-HER2 sdAb (99m-Tc-NM-02) for HER2 Expression Detection in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NanoMab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, dosimetry and efficacy of 99m-Tc labeled anti-HER2 single domain
      antibody (sdAb) (Product Code Name: 99mTc-NM-02) SPECT/CT imaging of HER2 expression in
      Breast Cancer and compare it with the existing gold standard &quot; HER2 expression detection&quot; by
      biopsy tissue immunohistochemistry (IHC) and/or Fluorescence In Situ Hybridization (FISH)
      method. It is also to establish a new clinical method of non-invasive HER2 expression
      detection in breast cancer using 99m-Tc labeled anti-HER2 sdAb
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Assessment of HER2 expression in Breast cancer using 99m-Tc-NM-02 SPECT/CT Scan</measure>
    <time_frame>1 year</time_frame>
    <description>Visual analysis will be carried out by 4 experienced nuclear medicine physicians to observe the uptake of 99m-Tc-NM-02 in breast malignant lesions. A 4 point system will be used to interpret the scans for abnormalities. It is categorised as such: score 0, no abnormal increased uptake; score 1, low increased uptake; score 2, moderate increased uptake; score 3, high increased uptake. The lesion will be considered positive for malignancy if the score is 2 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semiquantitative Assessment of Breast and other Metastatic Lesions in 99m-Tc-NM-02 SPECT/CT Scan</measure>
    <time_frame>1 year</time_frame>
    <description>Each subject will be administered 3-12 MBq/kg of 99m-Tc-NM-02 and the semiquantitative analysis of the region of interest (ROI) will be performed in breast and other metastatic lesions. Higher level of HER2 expression (Tumor proportion score, TPS), higher ROI in tumor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of 99m-Tc-NM-02 through Adverse Event Monitoring</measure>
    <time_frame>2 days</time_frame>
    <description>Subjects will be observed for safety after administration of 99mTc-NM-02, and will do follow up at 48h p.i. Subjects will do blood test to observe for abnormalities in clinical parameters and compare to baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of 99m-Tc-NM-02 through Adverse Event Monitoring</measure>
    <time_frame>7 days</time_frame>
    <description>Subjects will be observed for safety after administration of 99mTc-NM-02, and will do follow up at 7d p.i. Subjects will be contacted by investigator by phone and asked several questions related to subject's health after 99m-Tc-NM-02 injection and concomitant drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HER2 Expression Heterogeneity</measure>
    <time_frame>1 year</time_frame>
    <description>Biopsy tissue sample IHC and FISH HER2 test results from subject's primary tumor will indicate its HER2 expression level, this results will be compared with our radiotracer uptake in the primary tumor and will look for heterogeneity while observing for uptake in other metastatic lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Injection of 99m-Tc-NM-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99m-Tc-NM-02 (99m-Tc labeled anti-HER2 sdAb) in a single dose injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99m-Tc-NM-02 Injection</intervention_name>
    <description>Patient will be injected with microdose (&lt;100ug) of 99m-Tc-NM-02 radiotracer</description>
    <arm_group_label>Injection of 99m-Tc-NM-02</arm_group_label>
    <other_name>anti-HER2 SPECT/CT radiotracer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult female, age 18 years or older

          2. Prior diagnosis of breast cancer

          3. Willing to participate in this study and given written informed consent

          4. AST, ALT, BUN, Cr not more than double the normal values

          5. Subjects of childbearing potential must be willing to undergo a pregnancy test prior
             to enrolment

        Exclusion Criteria:

          1. Pregnancy (subjects with a positive pregnancy test at baseline screening period or who
             are planning to become pregnant during the study period)

          2. Breastfeeding (subjects in lactation)

          3. No biopsy tissue sample can be provided for HER2 expression detection

          4. Subjects with pacemakers

          5. Hepatitis B virus infection (including carriers) at screening, ie hepatitis B surface
             antigen (HBsAg) positive, or hepatitis C antibody (anti-HCV) positive, or acquired
             immunodeficiency disease (HIV) infected, or serum syphilis positive person

          6. Abnormal liver function during baseline screening period : AST or ALT&gt; 2 times the
             upper limit of normal value (ULN), if the marginal increase of a single index is
             judged as having no clinical significance by the investigator, it can be retested
             during the screening period. Once, if ≤ 2 times ULN after retesting, consider
             enrolling).

          7. Impaired renal function during screening: serum creatinine or urea nitrogen &gt; 1.5
             times ULN.

          8. Within 4 months prior to the baseline screening period , myocardial infarction or
             other cardiac events requiring hospitalization (unstable angina, etc.),
             cerebrovascular accident, transient ischemic attack, acute congestive Heart failure or
             severe arrhythmia (ventricular arrhythmia, atrioventricular block above II)

          9. Subjects with pulmonary embolism or deep vein thrombosis

         10. Various infections that the investigators consider unsuitable for study, including but
             not limited to patients with various infections requiring further treatment, such as
             urinary tract infections, respiratory infections, and diabetic foot infections.

         11. Patients with abnormal thyroid function during baseline screening period (including
             but not limited to active hyperthyroidism, hypothyroidism or Hashimoto's thyroiditis)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinhua Zhao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital Nuclear Medicine Dept</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinhua Zhao, PhD</last_name>
    <phone>0086-21-63240090</phone>
    <phone_ext>4940</phone_ext>
    <email>zhaojinhua1963@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhua Zhao, PhD</last_name>
      <phone>0086-21-63240090</phone>
      <phone_ext>4940</phone_ext>
      <email>zhaojinhua1963@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglehart JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 Jul;22(7):723-6. doi: 10.1038/nm.4120. Epub 2016 Jun 6.</citation>
    <PMID>27270588</PMID>
  </reference>
  <reference>
    <citation>Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20;353(16):1652-4.</citation>
    <PMID>16236735</PMID>
  </reference>
  <reference>
    <citation>Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. doi: 10.1038/nrclinonc.2011.177. Review.</citation>
    <PMID>22124364</PMID>
  </reference>
  <reference>
    <citation>Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.</citation>
    <PMID>25693012</PMID>
  </reference>
  <reference>
    <citation>Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M. HER2-positive breast cancer is lost in translation: time for patient-centered research. Nat Rev Clin Oncol. 2017 Nov;14(11):669-681. doi: 10.1038/nrclinonc.2017.96. Epub 2017 Aug 1. Review.</citation>
    <PMID>28762384</PMID>
  </reference>
  <reference>
    <citation>Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017 Jun 17;389(10087):2415-2429. doi: 10.1016/S0140-6736(16)32417-5. Epub 2016 Dec 7. Review.</citation>
    <PMID>27939064</PMID>
  </reference>
  <reference>
    <citation>Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012 Feb 20;30(6):593-9. doi: 10.1200/JCO.2010.33.8889. Epub 2011 Nov 28.</citation>
    <PMID>22124109</PMID>
  </reference>
  <reference>
    <citation>Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010 Jun;51(6):892-7. doi: 10.2967/jnumed.109.073239. Epub 2010 May 19.</citation>
    <PMID>20484419</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhao Jin Hua, MD</investigator_full_name>
    <investigator_title>Director Department of Nuclear Medicine, Principal Investigator, Professor</investigator_title>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>single domain antibody (sdAb)</keyword>
  <keyword>SPECT/CT imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

